April 16, 2024
The longevity company Gero has presented its new nonprofit initiative: a series of studies using the company’s aging clock, which is based on stepping patterns obtained from phones and wearables. One small step for man, one giant leap for aging research? Gero, an AI longevity company, has announced a new non-profit initiative named GeroSense Studies....
October 23, 2023
Gero, a biotechnology company focused on aging and chronic diseases, has closed $6M in a Series A extension round. This funding round positions Gero to continue internal drug development programs, grow its scientific team to boost platform technology development, and expand its US presence. The round was led by Melnichek Investments, a Cyprus-based VC firm that...
July 11, 2023
Peter Fedichev, co-founder and CEO of Gero, is a relative newcomer to the field of geroscience with a background in physics and not in biology. However, Peter has firmly established himself and Gero in the longevity landscape by twice publishing in Nature, entering a lucrative collaboration with Pfizer, and proposing a new aging-related theory. We...